Uncategorized
Aerie Pharmaceuticals reports net loss of $23.2 million in second quarter
Aerie Pharmaceuticals reported a net loss attributable to common stockholders of $23.2 million, or $0.87 per share, in the second quarter compared with a net loss of $18.8 million, or $0.73 per share, in the same period last year, according to a press release.The net loss was attributed to $13.3 million in research and development expenses and $9.4 million in general and administrative expenses. Higher operating expenses compared with last year included expansion of the company’s employee base to support growth of operations.